Last reviewed 2026-05-14 · How we verify

Investigator's Choice Chemotherapy

Investigator's Choice Chemotherapy is a Small molecule drug developed by Genmab. It is currently in Phase 3 development for Variable depending on investigator selection; typically used as a control arm in Phase 3 oncology trials. Also known as: BR or R-GemOx.

Investigator's Choice Chemotherapy refers to a flexible treatment approach where the investigating physician selects from approved chemotherapy regimens based on patient and tumor characteristics.

Investigator's Choice Chemotherapy refers to a flexible treatment approach where the investigating physician selects from approved chemotherapy regimens based on patient and tumor characteristics. Used for Variable depending on investigator selection; typically used as a control arm in Phase 3 oncology trials.

At a glance

Mechanism of action

This is not a single drug entity but rather a trial design framework allowing investigators to choose standard-of-care chemotherapy agents (such as platinum-based, taxane, or other cytotoxic drugs) as a comparator or control arm. The specific mechanism depends on which chemotherapy agent(s) the investigator selects, typically targeting rapidly dividing cancer cells through DNA damage or mitotic disruption.

Approved indications

• Variable depending on investigator selection; typically used as a control arm in Phase 3 oncology trials

Common side effects

• Myelosuppression
• Nausea and vomiting
• Alopecia
• Peripheral neuropathy
• Fatigue

Key clinical trials

• A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
• Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (PHASE3)
• A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (PHASE3)
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Investigator's Choice Chemotherapy CI brief — competitive landscape report
• Investigator's Choice Chemotherapy updates RSS · CI watch RSS
• Genmab portfolio CI

Frequently asked questions about Investigator's Choice Chemotherapy

Related

• Manufacturer: Genmab — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Variable depending on investigator selection; typically used as a control arm in Phase 3 oncology trials
• Also known as: BR or R-GemOx
• Compare: Investigator's Choice Chemotherapy vs similar drugs
• Pricing: Investigator's Choice Chemotherapy cost, discount & access